Anticholinergic or antispasmodic. Adults: 0.3-1.2 mg q 4-6 hr. Pediat-ric, over 41 kg: same as adult; 29.5-41 kg: 0.4 mg q 4-6 hr; 18.2-29.5 kg: 0.3 mg q 4-6 hr; 10.9-18.2 kg: 0.2 mg q 4-6 hr; 7.3-10.9 kg: 0.15 mg q 4-6 hr; 3.2-7.3 kg: 0.1 mg q 4-6 hr.

Prophylaxis of respiratory tract secretions and excess salivation during anesthesia. Adults: 2 mg.

Parkinsonism. Adults: 0.1-0.25 mg q.i.d.

Adults, IM, IV, SC: 0.4-0.6 mg q 4-6 hr. Pediatric, SC: 0.01 mg/kg, not to exceed 0.4 mg (or 0.3 mg/m2).

To reverse curariform blockade. Adults, IV: 0.6-1.2 mg given at the same time or a few minutes before 0.5-2 mg neostigmine methylsulfate (use separate syringes).

Treatment of toxicity from choli-nesterase inhibitors. Adults, IV, initial: 2-4 mg; then, 2 mg repeated q 5-10 min until musca-rinic symptoms disappear and signs of atropine toxicity begin to appear. Pediatric, IM, IV, initial: 1 mg; then, 0.5-1 mg q 5-10 min until muscarinic symptoms disappear and signs of atropine toxicity appear.

Treatment of mushroom poisoning due to muscarine. Adults, IM, IV: 1-2 mg q hr until respiratory effects decrease.

Treatment of organophosphate poisoning.

Adults, IM, IV, initial: 1-2 mg; then, repeat in 20-30 min (as soon as cyanosis has disappeared). Dosage may be continued for up to 2 days until symptoms improve.

Arrhythmias. Pediatric, IV: 0.01-0.03 mg/kg.

Prophylaxis of respiratory tract secretions, excessive salivation, suc-cinylcholine- or surgical procedure-induced arrhythmias. Pediatric, up to 3 kg, SC: 0.1 mg; 7-9 kg: 0.2 mg; 12-16 kg: 0.3 mg; 20-27 kg: 0.4 mg; 32 kg: 0.5 mg; 41 kg: 0.6 mg.

0 0

Post a comment